AZD 4831

Drug Profile

AZD 4831

Alternative Names: AZD4831

Latest Information Update: 16 Jan 2017

Price : $50

At a glance

  • Originator AstraZeneca
  • Class Cardiotonics; Cardiovascular therapies; Small molecules
  • Mechanism of Action Peroxidase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Heart failure

Most Recent Events

  • 05 Jan 2017 AstraZeneca terminates a phase-I clinical trial in Heart failure (In volunteers) in Germany (PO) (NCT02712372)
  • 09 Nov 2016 AstraZeneca suspends enrolment in a phase-I clinical trial in Heart failure (In volunteers) in Germany (PO) (NCT02712372)
  • 01 Jun 2016 Phase-I clinical trials in Heart failure (In volunteers) in Germany (PO) (NCT02712372)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top